Financial Data and Key Metrics Changes - For Q4 2021, the company reported revenue of $2.5 million, a significant increase from $1.1 million in Q4 2020, representing a year-over-year growth of approximately 127% [15] - Total operating expenses for Q4 2021 were $15.9 million, compared to $14.2 million in Q4 2020 [15] - The net loss attributable to common stockholders for Q4 2021 was $15.9 million, or $0.07 per share, compared to a net loss of $13.8 million, or $0.13 per share in Q4 2020 [15][16] - The adjusted net loss for Q4 2021 was $15.7 million, or $0.07 per share, compared to an adjusted net loss of $9.7 million, or $0.09 per share in Q4 2020 [16] - As of December 31, 2021, the company had cash and investments of approximately $135.8 million [16] Business Line Data and Key Metrics Changes - The company expanded its installed base by approximately 33% and increased procedure volumes by 44% in 2021 [7][17] - In 2021, over 2,100 procedures were performed, marking the highest annual procedure volume since the inception of the Senhance system [9] - In Q4 2021, over 500 procedures were performed using Senhance, representing a 30% increase compared to Q4 2020 [10] Market Data and Key Metrics Changes - The U.S. market saw a 95% growth in procedure volumes, while the EMEA region grew by 42% and Asia by 18% compared to 2020 [9] - General surgery accounted for 40% of case volumes, with gynecology, urology, bariatric, and colorectal procedures making up the remaining 60% [10] Company Strategy and Development Direction - The company aims to drive increased awareness of the Senhance platform and publish impactful clinical data to support its adoption [17][18] - Key focus areas for 2022 include market development, portfolio expansion, and technological advancements [18][20] - The company plans to add 10 to 12 new system initiations globally in 2022 and continue to invest in surgeon training and medical education [20][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing challenges due to COVID-19, including hospital restrictions and staffing shortages, but expressed optimism about continued growth in procedure volumes [6][32] - The company is focused on leveraging clinical data to demonstrate the value of the Senhance system and expects to see growth in foundational sites throughout 2022 [23][29] Other Important Information - The company received 510(k) clearance for expanded capabilities of the Intelligent Surgical Unit and for 5-millimeter articulating instruments, enhancing the system's dexterity [11][12] - The launch of Senhance Connect, a mobile in-OR communication system, has been well-received and is expected to facilitate better collaboration during surgeries [12] Q&A Session Summary Question: How is the last 60 days looking in terms of procedure volume? - Management indicated steady volume growth but noted unpredictability due to COVID-related fluctuations [32] Question: What is the pediatric market opportunity? - Management acknowledged a significant opportunity in pediatrics, particularly in Europe, and plans to file for pediatric indication in the U.S. [33][35] Question: What is the financial impact from Russia's invasion of Ukraine? - Management stated that while there will be an impact, the extent is still undetermined [38] Question: How do you see outright sales versus sale and leaseback strategies evolving? - Management expects a mix of both outright sales and leaseback strategies, with a slight preference for direct sales as hospital budgets recover [40][41] Question: Have supply chain issues improved in 2022? - Management reported ongoing challenges with supply chains, particularly in semiconductors and medical plastics, with no clear improvement yet [43]

Asensus Surgical, Inc. (NYSE:ASXC) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Mark Klausner - Westwicke, Investor Relations Anthony Fernando - President & Chief Executive Officer Shameze Rampertab - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Thank you for standing by. This is the conference operator. Welcome to the Asensus Third Quarter Financial and Operating Results Conference Call. As a reminder, all partic ...

Asensus Surgical, Inc. (NYSE:ASXC) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Mark Klausner - Westwicke, Investor Relations Anthony Fernando - President & Chief Executive Officer Shameze Rampertab - Chief Financial Officer Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Asensus Surgical, Inc. Second Quarter 2021 Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will cond ...

Financial Data and Key Metrics Changes - For Q1 2021, the company reported revenue of $2.1 million, up from $0.6 million in Q1 2020, with system revenue contributing $1.3 million, instruments and accessories $0.4 million, and services $0.4 million [10] - Total operating expenses decreased to $14.4 million in Q1 2021 from $16.0 million in Q1 2020 [10] - Net loss attributable to common stockholders was $17.3 million or $0.08 per share in Q1 2021, compared to a net loss of $17 million or $0.59 per share in Q1 2020 [11] - Adjusted net loss was $12.2 million or $0.06 per share in Q1 2021, compared to an adjusted net loss of $12 million or $0.41 per share in Q1 2020 [11] - Cash and cash equivalents and restricted cash were approximately $166.4 million as of March 31, 2021, extending the cash runway into 2024 [12] Business Line Data and Key Metrics Changes - The company signed two new lease agreements with hospitals in Europe and had its first lease buyout in Japan during the quarter, indicating progress in its business model [8][9] - Over 500 procedures were completed globally, with significant growth in procedure volumes in both the U.S. (over 60% growth) and Asia (over 40% growth) compared to Q1 2020 [17] - The number of foundational sites increased from 11 to 13 by the end of Q1 2021, demonstrating the growing adoption of the Senhance System [19] Market Data and Key Metrics Changes - Europe faced strong COVID-19 headwinds, yet over 50% of the overall case volume was performed there during the quarter [18] - The company experienced a broad mix of procedures across general, gynecology, and colorectal surgeries, validating the applicability of the Senhance System [18] Company Strategy and Development Direction - The company aims to continue market development for the Senhance System and expand its portfolio while advancing technology [14] - The goal for 2021 is to install 10 to 12 new Senhance Systems, despite challenges posed by COVID-19 [16] - The company achieved regulatory milestones, including CE marking and FDA clearance for expanded general surgery indications, which will enhance growth opportunities [21] Management Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing challenges from COVID-19 but expressed confidence in the robust pipeline and the ability to meet system installation goals [16][28] - The company expects an increase in case volume as elective procedures become more widely performed and anticipates less challenging conditions for new system installations as restrictions are lifted [28] Other Important Information - The company introduced Senhance Connect, a mobile communication system for surgeons, which enhances interoperative communication and training opportunities [22][25] - The company is focused on performance-guided surgery development, with positive feedback on the initial application of the ISU [26] Q&A Session Summary Question: Dynamics behind the lease buyout in Japan - Management explained that the hospital in Japan decided to buy out the lease after performing over 100 cases, demonstrating the economic advantages of the Senhance System [33] Question: Granularity on the 500 procedures performed - Management indicated that the procedures were spread across various specialties, including gynecology and general surgery, with a mix of simple and complex cases [35] Question: Expectations for foundational sites growth - Management expressed optimism about increasing foundational sites but acknowledged uncertainty due to ongoing COVID-19 impacts in different regions [38]